# An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing

> **NCT07141771** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 100 (estimated)

## Conditions studied

- SCLC, Extensive Stage

## Interventions

- **DRUG:** Serplulimab
- **DRUG:** Fluzoparib
- **DRUG:** Topotecan/Irinotecan/Paclitaxel/Temozolomide
- **DRUG:** Etoposide/Carboplatin/Cisplatin
- **DRUG:** Lurbinectedin
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT07141771
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-31
- **Primary completion:** 2030-06-30
- **Final completion:** 2030-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07141771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07141771, "An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT07141771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*